STAT+: Roche ends Huntington’s gene-silencing programs
ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout
Read the full articleYou might also wanna read
A turning point for pancreatic cancer patients
Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
statnews.com·1mo ago
Illumina Doubles Down on Newborn Sequencing: Ion Genomics Newsletter, June 23, 2026
10x teams up with Cleveland Clinic, Norway embraces nanopore-based brain cancer dx, Guardant-TwinStrand legal update, a World Cup-related co
Caris Launches MCED Test: Ion Genomics Newsletter, July 1, 2026
German Merck buys Bio-Techne, lots of Natera news, July 17th happy hour, Springer Nature Sells SciAm, and more.
Roche ends 2 Huntington’s disease programs, including Ionis-partnered tominersen
Roche has halted development on two of its Huntington’s disease prospects, marking another blow for a patient community that has long awaite
Roche abandons two Huntington's drug candidates
Roche abandons two Huntington's drug candidates Phil.Taylor Fri, 10/07/2026 - 08:43
CRISPR takes a bold leap toward silencing Down syndrome's extra chromosome
Article URL: Comments URL: Points: 13 # Comments: 8
Comments
Sign in to join the conversation.
No comments yet. Be the first.